Immediate Impact

1 by Nobel laureates 1 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
2023 Standout
2 intermediate papers

Works of Robert L. Flucke being referenced

Forced Expiratory Flows and Volumes in Infants
2000
Adult-type pulmonary function tests in infants without respiratory disease
2000
and 1 more

Author Peers

Author Last Decade Papers Cites
Robert L. Flucke 611 34 16 185 108 9 665
A Barbato 630 26 2 94 190 10 716
Tarek Nakhla 554 104 225 27 14 764
Marie-Denise Schaller 378 49 5 121 74 10 575
Benjamin B. Ross 500 40 16 73 225 14 648
David Henson 312 14 5 100 78 17 846
Rebecca L. Mutich 500 49 2 381 50 22 632
Robert G. Zwerdling 546 12 2 339 30 15 696
R Ferranti 394 74 79 73 13 602
P. G. Fabricius 449 23 3 88 263 14 682
Michael Davies 583 14 6 62 221 21 766

All Works

Loading papers...

Rankless by CCL
2026